PFE Pfizer
Patent-cliff pharma priced for margin repair; fair only if cost cuts and oncology fully offset LOEs.
The story
Pfizer is a scaled, cash-generative big pharma that has worked through its COVID revenue collapse and now faces a 2026-2028 patent cliff (Eliquis, Ibrance, Xtandi and others, roughly $17B of revenue at risk). Seagen oncology, the vaccines franchise, Metsera obesity assets and about $7B+ of cost cuts are meant to offset that. It is a mature, ex-growth franchise. Its moat is R&D scale, distribution and a deal-making balance sheet, and that balance sheet is now stretched by about $63B of net debt. Value depends on restoring margins while revenue stays roughly flat, not on growth.
Growth and reinvestment are kept from last time because the patent-cliff facts have not changed. I raised the target margin from 25% to 28% because GAAP EBIT is weighed down by roughly $5B+ of acquisition amortization and IPR&D, while cash-based margins already run in the low 30s. I raised beta from 0.65 to 0.75 to move it toward the 0.95 industry anchor given the heavy leverage. Together these address the prior take's implied >100% gap to the market.
Value drivers
| Revenue growth (Y1) | -4.0% |
| Terminal growth | 2.2% |
| Forecast horizon | 8y |
| Target operating margin | 28.0% |
| Years to target margin | 6 |
| Sales-to-capital | 1.20 |
| Beta | 0.75 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 10.1% |
Valuation bridge
| PV of explicit FCFF | 67.99B |
| PV of terminal value | 83.02B |
| Equity value | 86.13B |
| ÷ shares → per share | $15.11 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 61.15B | -4.0% | 13.7% | 8.38B | 0 | 8.38B | 7.67B |
| 2 | 59.24B | -3.1% | 16.6% | 9.81B | 0 | 9.81B | 8.22B |
| 3 | 57.92B | -2.2% | 19.4% | 11.25B | 0 | 11.25B | 8.63B |
| 4 | 57.14B | -1.3% | 22.3% | 12.73B | 0 | 12.73B | 8.94B |
| 5 | 56.88B | -0.5% | 25.1% | 14.30B | 0 | 14.30B | 9.19B |
| 6 | 57.13B | 0.4% | 28.0% | 16.00B | 203.16M | 15.79B | 9.29B |
| 7 | 57.88B | 1.3% | 28.0% | 16.21B | 625.68M | 15.58B | 8.39B |
| 8 | 59.15B | 2.2% | 28.0% | 16.56B | 1.06B | 15.50B | 7.64B |
Key risks
- Patent-cliff erosion (Eliquis, Ibrance, Xtandi) outruns launches and cost cuts
- Seagen/Metsera pipeline disappointments forcing further write-downs or costly M&A
- Net debt of about $63B limits flexibility and squeezes the dividend if cash flow slips
- US drug pricing pressure (IRA negotiation, MFN policies)
Catalysts
- Execution on cost cuts lifting operating margin toward the high 20s
- Positive late-stage oncology ADC or obesity readouts
- Deleveraging that restores M&A and buyback capacity